Deformable Nanovesicles Synthesized through an Adaptable Microfluidic Platform for Enhanced Localized Transdermal Drug Delivery.

Journal of drug delivery Pub Date : 2017-01-01 Epub Date: 2017-04-05 DOI:10.1155/2017/4759839
Naren Subbiah, Jesus Campagna, Patricia Spilman, Mohammad Parvez Alam, Shivani Sharma, Akishige Hokugo, Ichiro Nishimura, Varghese John
{"title":"Deformable Nanovesicles Synthesized through an Adaptable Microfluidic Platform for Enhanced Localized Transdermal Drug Delivery.","authors":"Naren Subbiah,&nbsp;Jesus Campagna,&nbsp;Patricia Spilman,&nbsp;Mohammad Parvez Alam,&nbsp;Shivani Sharma,&nbsp;Akishige Hokugo,&nbsp;Ichiro Nishimura,&nbsp;Varghese John","doi":"10.1155/2017/4759839","DOIUrl":null,"url":null,"abstract":"<p><p>Phospholipid-based deformable nanovesicles (DNVs) that have flexibility in shape offer an adaptable and facile method to encapsulate diverse classes of therapeutics and facilitate localized transdermal delivery while minimizing systemic exposure. Here we report the use of a microfluidic reactor for the synthesis of DNVs and show that alteration of input parameters such as flow speeds as well as molar and flow rate ratios increases entrapment efficiency of drugs and allows fine-tuning of DNV size, elasticity, and surface charge. To determine the ability of DNV-encapsulated drug to be delivered transdermally to a local site, we synthesized, characterized, and tested DNVs carrying the fluorescently labeled hydrophilic bisphosphonate drug AF-647 zoledronate (AF647-Zol). AF647-Zol DNVs were lyophilized, resuspended, and applied topically as a paste to the calvarial skin of mice. High-resolution fluorescent imaging and confocal microscopy revealed significant increase of encapsulated payload delivery to the target tissue-cranial bone-by DNVs as compared to nondeformable nanovesicles (NVs) or aqueous drug solutions. Interestingly, NV delivery was not superior to aqueous drug solution. Our studies show that microfluidic reactor-synthesized DNVs can be produced in good yield, with high encapsulation efficiency, reproducibility, and stability after storage, and represent a useful vehicle for localized transdermal drug delivery.</p>","PeriodicalId":15575,"journal":{"name":"Journal of drug delivery","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2017/4759839","citationCount":"9","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of drug delivery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2017/4759839","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/4/5 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 9

Abstract

Phospholipid-based deformable nanovesicles (DNVs) that have flexibility in shape offer an adaptable and facile method to encapsulate diverse classes of therapeutics and facilitate localized transdermal delivery while minimizing systemic exposure. Here we report the use of a microfluidic reactor for the synthesis of DNVs and show that alteration of input parameters such as flow speeds as well as molar and flow rate ratios increases entrapment efficiency of drugs and allows fine-tuning of DNV size, elasticity, and surface charge. To determine the ability of DNV-encapsulated drug to be delivered transdermally to a local site, we synthesized, characterized, and tested DNVs carrying the fluorescently labeled hydrophilic bisphosphonate drug AF-647 zoledronate (AF647-Zol). AF647-Zol DNVs were lyophilized, resuspended, and applied topically as a paste to the calvarial skin of mice. High-resolution fluorescent imaging and confocal microscopy revealed significant increase of encapsulated payload delivery to the target tissue-cranial bone-by DNVs as compared to nondeformable nanovesicles (NVs) or aqueous drug solutions. Interestingly, NV delivery was not superior to aqueous drug solution. Our studies show that microfluidic reactor-synthesized DNVs can be produced in good yield, with high encapsulation efficiency, reproducibility, and stability after storage, and represent a useful vehicle for localized transdermal drug delivery.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
基于自适应微流控平台合成的可变形纳米囊泡增强局部经皮给药。
基于磷脂的可变形纳米囊泡(dnv)具有灵活的形状,提供了一种适应性强且简便的方法来封装各种类型的治疗药物,并促进局部透皮给药,同时最大限度地减少全身暴露。在这里,我们报告了使用微流控反应器合成DNV,并表明改变输入参数,如流速以及摩尔和流速比,可以提高药物的包载效率,并允许微调DNV的大小、弹性和表面电荷。为了确定dnv包膜药物经皮递送到局部部位的能力,我们合成、表征并测试了携带荧光标记的亲水性双膦酸盐药物AF-647唑来膦酸盐(AF647-Zol)的dnv。将AF647-Zol dnv冻干,重悬,并局部贴敷于小鼠颅骨皮肤。高分辨率荧光成像和共聚焦显微镜显示,与不可变形的纳米囊泡(NVs)或含水药物溶液相比,dnv对目标组织(颅骨)的封装有效载荷递送显著增加。有趣的是,NV的递送并不优于药物水溶液。我们的研究表明,微流控反应器合成的dnv产率高,包封效率高,重现性好,储存后稳定性好,是一种有效的局部透皮给药载体。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of drug delivery
Journal of drug delivery PHARMACOLOGY & PHARMACY-
自引率
0.00%
发文量
0
期刊最新文献
Corrigendum to "Alkyl Length Effects on the DNA Transport Properties of Cu (II) and Zn(II) Metallovesicles: An In Vitro and In Vivo Study". Dry Powder and Budesonide Inhalation Suspension Deposition Rates in Asthmatic Airway-Obstruction Regions. Rate of Drug Coating Dissolution Determines In-Tissue Drug Retention and Durability of Biological Efficacy. Alkyl Length Effects on the DNA Transport Properties of Cu (II) and Zn(II) Metallovesicles: An In Vitro and In Vivo Study. Potential of Cocoa Pod Husk Pectin-Based Modified Release Capsules as a Carrier for Chronodelivery of Hydrocortisone in Sprague-Dawley Rats.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1